Your browser doesn't support javascript.
loading
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Babiker, Hani; Borazanci, Erkut; Subbiah, Vivek; Agarwala, Sanjiv; Algazi, Alain; Schachter, Jacob; Lotem, Michael; Maurice-Dror, Corinne; Hendler, Daniel; Rahimian, Shah; Minderman, Hans; Haymaker, Cara; Mahadevan, Daruka; Bernatchez, Chantale; Murthy, Ravi; Hultsch, Rolf; Kaplan, Nadia; Woodhead, Gregory; Hennemeyer, Charles; Chunduru, Srinivas; Anderson, Peter M; Diab, Adi; Puzanov, Igor.
Affiliation
  • Babiker H; Mayo Clinic, Jacksonville, Florida.
  • Borazanci E; HonorHealth Research Institute, Scottsdale, Arizona.
  • Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Agarwala S; Saint Luke's University Health Network, Easton, Pennsylvania.
  • Algazi A; University of California, San Francisco, California.
  • Schachter J; Sheba Medical Center, Tel HaShomer, Israel.
  • Lotem M; Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Maurice-Dror C; Rambam Health, Haifa, Israel.
  • Hendler D; Rabin Medical Center, Petach Tikva, Israel.
  • Rahimian S; Idera Pharmaceuticals, Inc., Exton, Pennsylvania.
  • Minderman H; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Haymaker C; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mahadevan D; University of Texas Health, San Antonio, Texas.
  • Bernatchez C; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Murthy R; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hultsch R; HonorHealth Research Institute, Scottsdale, Arizona.
  • Kaplan N; Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Woodhead G; University of Arizona, Tucson, Arizona.
  • Hennemeyer C; University of Arizona, Tucson, Arizona.
  • Chunduru S; Idera Pharmaceuticals, Inc., Exton, Pennsylvania.
  • Anderson PM; Cleveland Clinic, Cleveland, Ohio.
  • Diab A; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Puzanov I; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Clin Cancer Res ; 28(23): 5079-5087, 2022 12 01.
Article in En | MEDLINE | ID: mdl-35917516
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma / Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma / Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States